CTI BioPharma Corp. (CTIC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

5.79

+0.08

(+1.40%)

At close: 04:00PM EDT

5.82

+0.03

(+0.52%)

After hours:

07:44PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Momentum

View all chart patterns

Performance Outlook

Previous Close	5.71
Open	5.73
Bid	5.78 x 3000
Ask	5.86 x 800
Day's Range	5.63 - 5.92
52 Week Range	1.43 - 7.80
Volume	4,092,026
Avg. Volume	4,923,851

Market Cap	662.289M
Beta (5Y Monthly)	0.87
PE Ratio (TTM)	N/A
EPS (TTM)	-1.23
Earnings Date	Nov 10, 2022 - Nov 14, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	10.41

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CTIC

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

CTI BioPharma Corp.
Analyst Report: Bristol-Myers Squibb CompanyBristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Rating
Fair Value
Economic Moat
10 days agoMorningstar

All

Motley Fool
Why CTI BioPharma Stock Got Rocked on Tuesday
A big revenue beat couldn't make up for a modest bottom-line miss on Tuesday for CTI BioPharma (NASDAQ: CTIC). This is CTI's drug that was approved by the Food and Drug Administration (FDA) in March for the treatment of myelofibrosis, a rare bone marrow disorder.
Zacks
CTI BioPharma (CTIC) Reports Q2 Loss, Tops Revenue Estimates
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5% and 20.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Fabrinet (FN) to Report Q4 Earnings: What's in the Cards?
  Zacks
- Shopify Inc. (SHOP) is Attracting Investor Attention: Here is What You Should Know
  Zacks
PR Newswire
CTI BioPharma Reports Second Quarter 2022 Financial Results
CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the second quarter ended June 30, 2022.